Clotrimazole and efaroxan inhibit red cell Gardos channel independently of imidazoline I1 and I2 binding sites.
In the present report, we investigated the potential involvement of imidazoline I1 and I2 binding sites in the inhibition of the Ca(2+)-activated K+ channel (Gardos channel) by clotrimazole in human red cells. Ca(2+)-activated 86Rb influx was inhibited by clotrimazole and efaroxan but not by the imidazoline binding site ligands clonidine, moxonidine, cirazoline and idazoxan (100 microM). Binding studies with [3H]idazoxan and [3H]p-aminoclonidine did not reveal the expression of I1 and I2 binding sites in erythrocytes. These data indicate that the effects of clotrimazole and efaroxan on the erythrocyte Ca(2+)-activated K+ channel may be mediated by a 'non-I1/non-I2' binding site.
Coupry
I
I
INSERM U388, Institut Louis Bugnard, CHU Rangueil, Toulouse, France.
Armsby
C C
CC
Alper
S L
SL
Brugnara
C
C
Parini
A
A
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D001665:Binding Sites; D002118:Calcium / Q000494:pharmacology; D003022:Clotrimazole / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007093:Imidazoles / Q000378:metabolism* / Q000494:pharmacology*; D015221:Potassium Channels / Q000187:drug effects*
D000317:Adrenergic alpha-Antagonists; D001572:Benzofurans; D007093:Imidazoles; D015221:Potassium Channels; C062597:efaroxan; D003022:Clotrimazole; D002118:Calcium